Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Aug;40(8):1860–1865. doi: 10.1128/aac.40.8.1860

Development and evaluation of a Bayesian pharmacokinetic estimator and optimal, sparse sampling strategies for ceftazidime.

A D Kashuba 1, C H Ballow 1, A Forrest 1
PMCID: PMC163430  PMID: 8843294

Abstract

Data were gathered during an activity-controlled trial in which seriously ill, elderly patients were randomized to receive intravenous ceftazidime or ciprofloxacin and for which adaptive feedback control of drug concentrations in plasma and activity profiles was prospectively performed. The adaptive feedback control algorithm for ceftazidime used an initial population model, a maximum a posteriori (MAP)-Bayesian pharmacokinetic parameter value estimator, and an optimal, sparse sampling strategy for ceftazidime that had been derived from data in the literature obtained from volunteers. Iterative two-stage population pharmacokinetic analysis was performed to develop an unbiased MAP-Bayesian estimator and updated optimal, sparse sampling strategies. The final median values of the population parameters were follows: the volume of distribution of the central compartment was equal to 0.249 liter/kg, the volume of distribution of the peripheral compartment was equal to 0.173 liter/kg, the distributional clearance between the central and peripheral compartments was equal to 0.2251 liter/h/kg, the slope of the total clearance (CL) versus the creatinine clearance (CLCR) was equal to 0.000736 liter/h/kg of CL/1 ml/min/1.73 m2 of CLCR, and nonrenal clearance was equal to + 0.00527 liter/h/kg. Optimal sampling times were dependent on CLCR; for CLCR of > or = 30 ml/min/1.73 m2, the optimal sampling times were 0.583, 3.0, 7.0, and 16.0 h and, for CLCR of < 30 ml/min/1.73 m2, optimal sampling times were 0.583, 4.15, 11.5, and 24.0 h. The study demonstrates that because pharmacokinetic information from volunteers may often not be reflective of specialty populations such as critically ill elderly individuals, iterative two-stage population pharmacokinetic analysis, MAP-Bayesian parameter estimation, and optimal, sparse sampling strategy can be important tools in characterizing their pharmacokinetics.

Full Text

The Full Text of this article is available as a PDF (230.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Briggs W. L., Phelps R. W., Swanson G. D. A probabilistic approach to the single-point, single-dose problem. IEEE Trans Biomed Eng. 1990 Jan;37(1):80–84. doi: 10.1109/10.43619. [DOI] [PubMed] [Google Scholar]
  2. Bruno R., Iliadis M. C., Lacarelle B., Cosson V., Mandema J. W., Le Roux Y., Montay G., Durand A., Ballereau M., Alasia M. Evaluation of Bayesian estimation in comparison to NONMEM for population pharmacokinetic data analysis: application to pefloxacin in intensive care unit patients. J Pharmacokinet Biopharm. 1992 Dec;20(6):653–669. doi: 10.1007/BF01064424. [DOI] [PubMed] [Google Scholar]
  3. D'Argenio D. Z. Optimal sampling times for pharmacokinetic experiments. J Pharmacokinet Biopharm. 1981 Dec;9(6):739–756. doi: 10.1007/BF01070904. [DOI] [PubMed] [Google Scholar]
  4. D'Argenio D. Z., Schumitzky A. A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Programs Biomed. 1979 Mar;9(2):115–134. doi: 10.1016/0010-468x(79)90025-4. [DOI] [PubMed] [Google Scholar]
  5. Debord J., Voultoury J. C., Lachatre G., Gay C., Favereau J. P., Gay R. Population pharmacokinetic parameters for Bayesian monitoring of amikacin therapy in intensive care unit patients. Eur J Clin Pharmacol. 1992;43(4):435–436. doi: 10.1007/BF02220623. [DOI] [PubMed] [Google Scholar]
  6. Drusano G. L., Forrest A., Snyder M. J., Reed M. D., Blumer J. L. An evaluation of optimal sampling strategy and adaptive study design. Clin Pharmacol Ther. 1988 Aug;44(2):232–238. doi: 10.1038/clpt.1988.142. [DOI] [PubMed] [Google Scholar]
  7. Drusano G. L., Standiford H. C., Fitzpatrick B., Leslie J., Tangtatsawasdi P., Ryan P., Tatem B., Moody M. R., Schimpff S. C. Comparison of the pharmacokinetics of ceftazidime and moxalactam and their microbiological correlates in volunteers. Antimicrob Agents Chemother. 1984 Sep;26(3):388–393. doi: 10.1128/aac.26.3.388. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Forrest A., Ballow C. H., Nix D. E., Birmingham M. C., Schentag J. J. Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin. Antimicrob Agents Chemother. 1993 May;37(5):1065–1072. doi: 10.1128/aac.37.5.1065. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Forrest A., Nix D. E., Ballow C. H., Goss T. F., Birmingham M. C., Schentag J. J. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother. 1993 May;37(5):1073–1081. doi: 10.1128/aac.37.5.1073. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Gentry L. O. Antimicrobial activity, pharmacokinetics, therapeutic indications and adverse reactions of ceftazidime. Pharmacotherapy. 1985 Sep-Oct;5(5):254–267. doi: 10.1002/j.1875-9114.1985.tb03424.x. [DOI] [PubMed] [Google Scholar]
  11. Guay D. R., Vance-Bryan K., Gilliland S., Rodvold K., Rotschafer J. Comparison of vancomycin pharmacokinetics in hospitalized elderly and young patients using a Bayesian forecaster. J Clin Pharmacol. 1993 Oct;33(10):918–922. doi: 10.1002/j.1552-4604.1993.tb01922.x. [DOI] [PubMed] [Google Scholar]
  12. Jelliffe R. W., Schumitzky A., Van Guilder M., Liu M., Hu L., Maire P., Gomis P., Barbaut X., Tahani B. Individualizing drug dosage regimens: roles of population pharmacokinetic and dynamic models, Bayesian fitting, and adaptive control. Ther Drug Monit. 1993 Oct;15(5):380–393. [PubMed] [Google Scholar]
  13. Jonsson M., Walder M. Pharmacokinetics of ceftazidime in acutely ill hospitalised elderly patients. Eur J Clin Microbiol Infect Dis. 1992 Jan;11(1):15–21. doi: 10.1007/BF01971265. [DOI] [PubMed] [Google Scholar]
  14. Kinowski J. M., de la Coussaye J. E., Bressolle F., Fabre D., Saissi G., Bouvet O., Galtier M., Eledjam J. J. Multiple-dose pharmacokinetics of amikacin and ceftazidime in critically ill patients with septic multiple-organ failure during intermittent hemofiltration. Antimicrob Agents Chemother. 1993 Mar;37(3):464–473. doi: 10.1128/aac.37.3.464. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Kosirog J. L., Rospond R. M., Destache C., Hall P. Aminoglycoside forecasting in neutropenic patients with cancer. Clin Pharmacokinet. 1993 Jan;24(1):79–87. doi: 10.2165/00003088-199324010-00007. [DOI] [PubMed] [Google Scholar]
  16. Myers C. M., Blumer J. L. Determination of ceftazidime in biological fluids by using high-pressure liquid chromatography. Antimicrob Agents Chemother. 1983 Sep;24(3):343–346. doi: 10.1128/aac.24.3.343. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. O'Callaghan C. H., Acred P., Harper P. B., Ryan D. M., Kirby S. M., Harding S. M. GR 20263, a new broad-spectrum cephalosporin with anti-pseudomonal activity. Antimicrob Agents Chemother. 1980 May;17(5):876–883. doi: 10.1128/aac.17.5.876. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Paradis D., Vallée F., Allard S., Bisson C., Daviau N., Drapeau C., Auger F., LeBel M. Comparative study of pharmacokinetics and serum bactericidal activities of cefpirome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin. Antimicrob Agents Chemother. 1992 Oct;36(10):2085–2092. doi: 10.1128/aac.36.10.2085. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Schentag J. J., Nix D. E., Adelman M. H. Mathematical examination of dual individualization principles (I): Relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin. DICP. 1991 Oct;25(10):1050–1057. doi: 10.1177/106002809102501003. [DOI] [PubMed] [Google Scholar]
  20. Sheiner L. B., Beal S. L. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981 Aug;9(4):503–512. doi: 10.1007/BF01060893. [DOI] [PubMed] [Google Scholar]
  21. Sirgo M. A., Norris S. Ceftazidime in the elderly: appropriateness of twice-daily dosing. DICP. 1991 Mar;25(3):284–288. doi: 10.1177/106002809102500313. [DOI] [PubMed] [Google Scholar]
  22. Steimer J. L., Mallet A., Golmard J. L., Boisvieux J. F. Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed-effect model. Drug Metab Rev. 1984;15(1-2):265–292. doi: 10.3109/03602538409015066. [DOI] [PubMed] [Google Scholar]
  23. Thomson A. H., Whiting B. Bayesian parameter estimation and population pharmacokinetics. Clin Pharmacokinet. 1992 Jun;22(6):447–467. doi: 10.2165/00003088-199222060-00004. [DOI] [PubMed] [Google Scholar]
  24. Uematsu T. Population pharmacokinetic analysis of new aminoglycosides, astromicin and isepamicin, and evaluation of Bayesian prediction method for approximation of individual clearance of drug. Int J Clin Pharmacol Ther Toxicol. 1993 Dec;31(12):606–610. [PubMed] [Google Scholar]
  25. Welage L. S., Schultz R. W., Schentag J. J. Pharmacokinetics of ceftazidime in patients with renal insufficiency. Antimicrob Agents Chemother. 1984 Feb;25(2):201–204. doi: 10.1128/aac.25.2.201. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Yamaoka K., Nakagawa T., Uno T. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm. 1978 Apr;6(2):165–175. doi: 10.1007/BF01117450. [DOI] [PubMed] [Google Scholar]
  27. van Dalen R., Vree T. B. Pharmacokinetics of antibiotics in critically ill patients. Intensive Care Med. 1990;16 (Suppl 3):S235–S238. doi: 10.1007/BF01709707. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES